Jessop J D
Rheumatol Rehabil. 1976;Suppl:37-42. doi: 10.1093/rheumatology/15.5.37.
A series of 26 patients with ankylosing spondylitis have been included in a double-blind cross-over comparison of ketoprofen 200 mg daily and phenylbutazone 300 mg daily, each drug being given for 4 weeks, with paracetamol as a 'rescue drug'. Six patients withdrew from the study: three on phenylbutazone and one on ketoprofen--two defaulted treatment. Twenty patients (17 males and 3 females) were eligible for assessment. Their ages ranged between 20 and 59 years (mean 40.2 years). Patient characteristics were comparable in both groups. The results of this series indicate no suggestion of statistically significant differences in any of the nine movements measured. The only significant differences, both in favour of phenylbutazone, were in the paracetamol consumption in the second treatment period in the group receiving ketoprofen first (0.01 greater than P greater than 0.005) and in the patients' preference for phenylbutazone (0.005 greater than P greater than 0.001). Adverse reactions were comparable in both groups.
26例强直性脊柱炎患者参与了一项双盲交叉对照研究，比较每日服用200毫克酮洛芬和每日服用300毫克保泰松的效果，每种药物服用4周，对乙酰氨基酚作为“急救药物”。6例患者退出研究：3例服用保泰松，1例服用酮洛芬——2例未进行治疗。20例患者（17例男性和3例女性）符合评估条件。他们的年龄在20岁至59岁之间（平均40.2岁）。两组患者的特征具有可比性。该系列研究结果表明，在所测量的九项活动中，均未显示出统计学上的显著差异。唯一显著的差异均有利于保泰松，一是在先服用酮洛芬的组中，第二个治疗期的对乙酰氨基酚消耗量（0.01＞P＞0.005），二是患者对保泰松的偏好（0.005＞P＞0.001）。两组的不良反应具有可比性。
